Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Vomiting 1Breast Neoplasms 1

Interventions

Carboplatin 6anlotinib 5lenvatinib 4Oxaliplatin 4Immune Checkpoint Inhibitors 4Cisplatin 4tislelizumab 3sintilimab 3Fluorouracil 3Capecitabine 3venetoclax 2Rosuvastatin Calcium 2Prednisone 2Megestrol Acetate 2Leucovorin 2Drug Therapy 2Dexmedetomidine 2Dexamethasone 2Cyclophosphamide 2Bevacizumab 2Aspirin 2zanubrutinib 1xiaojin wan 1trastuzumab deruxtecan 1trametinib 1tocilizumab 1testosterone 17 beta-cypionate 1tenofovir alafenamide 1telitacicept 1taxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Not yet recruiting × fosaprepitant × Clear all
NCT05841849 2023-05-03

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 4 Not yet recruiting
1,028 enrolled
Breast

Breast Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡